Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on QNRX. Maxim Group reduced their price objective on Quoin Pharmaceuticals to $25.00 in a research report on Thursday, May 26th. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research report on Friday, May 6th. They set a "buy" rating and a $25.00 price objective for the company.
Quoin Pharmaceuticals Trading Down 3.2 %
NASDAQ:QNRX traded down $0.16 during midday trading on Thursday, reaching $4.82. 2,277,217 shares of the company traded hands, compared to its average volume of 658,277. Quoin Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $444.00. The company has a fifty day moving average price of $5.98 and a 200 day moving average price of $11.30.
Quoin Pharmaceuticals (NASDAQ:QNRX - Get Rating) last announced its quarterly earnings results on Monday, May 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter. Equities research analysts predict that Quoin Pharmaceuticals will post -6.5 EPS for the current year.